PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most common type of bladder cancer.1,2 This approval is based on results from the Phase 3 CheckMate –901 trial which evaluated Opdivo in combination with cisplatin and gemcitabine followed by O ...

Solskin Bristol-Myers Squibb Company (NYSE:BMY) has built momentum off its Q4 earnings report which shares up more than 11% in the past month. Compared to a difficult 2023 where the stock lost nearly a third of its value, the recent price action suggests bulls are back alongside an improving fundamental outlook. The story with BMY has been an ongoing shift in its drug portfolio between weaker sales from its legacy brands, balanced by stronger trends from new product launches. Favorably, the outlook is for a ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2024. Samit Hirawat, M.D., executive vice president, chief medical officer, Drug Development, will take part in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida, on Wednesday, March 13, 2024. He will answer questions about the company beginning at 10:00 a.m. ET. Lynelle Hoch, president, Cell Therap ...

If you’re searching for must-have stocks for wealth, look no further. In investing, identifying the right stocks leads to a fear of missing out. Here, in this labyrinth, treasures are unearthed – treasures that may lead to financial abundance. This is a blueprint or guidebook for high-return stocks that yield short-term gains and massive long-term wealth. These stocks are the crème de la crème of the market.From the life-saving pharmaceutical innovations of the first one to the tech juggernaut of the second ...

Bristol-Myers Squibb Company (NYSE:BMY) 44th Annual TD Cowen Healthcare Conference March 4, 2024 9:50 AM ET Company Participants Roland Chen - SVP and Head, Cardiovascular and Neuroscience Development, Global Drug Development Conference Call Participants Steve Scala - TD Cowen Steve Scala Well, good morning once again. We're delighted to have Bristol-Myers Squibb here at the Cowen 44th Annual Healthcare Conference, representing the company is Roland Chen, who's Senior Vice President and Head of Immunology, ...

Dividend Stocks That Could Deliver Life-Changing Returns relif / Getty Images 2022 was a dreadful year for investors, with the S&P 500 down almost 20% and the Nasdaq lower by a stunning 33%. What a difference a year can make. In 2023, the S&P 500 was up 24.2 %, with the longest weekly winning streak since 2004. The Nasdaq had an astounding 43.4% move higher, the most significant annual gain since 2020. The venerable Dow Jones Industrials came in up 13%.However, just ten companies have made up 95% of the g ...

In the latest trading session, Bristol Myers Squibb (BMY) closed at $50.89, marking a +0.28% move from the previous day. This change lagged the S&P 500's 0.8% gain on the day. Elsewhere, the Dow gained 0.23%, while the tech-heavy Nasdaq added 1.14%.The biopharmaceutical company's shares have seen an increase of 4.27% over the last month, surpassing the Medical sector's gain of 3.58% and falling behind the S&P 500's gain of 5.2%.Market participants will be closely following the financial results of Bristol M ...

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this biopharmaceutical company have returned +4.2% over the past month versus the Zacks S&P 500 composite's +3.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, has gained 2.3% over this period. Now the key question is: Where could the ...

NEW YORK--(BUSINESS WIRE)--Tapestry, Inc. (NYSE: TPR), a house of iconic accessories and lifestyle brands consisting of Coach, Kate Spade, and Stuart Weitzman, today announced that Kevin Hourican, President and Chief Executive Officer of Sysco Corporation (NYSE: SYY), and David Elkins, Executive Vice President and Chief Financial Officer of Bristol Myers Squibb (NYSE: BMY), have been appointed to the Company’s Board of Directors. The appointments of Mr. Hourican and Mr. Elkins to the Board bring the members ...

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023; increasing commercial access to KIMMTRAK globally, and pursuing future growth opportunities with two registrational trials in advanced cutaneous melanoma and adjuvant uveal melanoma Clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) with nivolumab in regi ...